Cantor Fitzgerald Forecasts Strong Price Appreciation for Centene (NYSE:CNC) Stock

Centene (NYSE:CNC) had its price objective hoisted by research analysts at Cantor Fitzgerald from $75.00 to $79.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s target price would suggest a potential upside of 14.85% from the stock’s current price.

Several other brokerages also recently issued reports on CNC. Zacks Research downgraded shares of Centene from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Royal Bank Of Canada lifted their target price on Centene from $70.00 to $71.00 and gave the company a “sector perform” rating in a research note on Thursday, July 9th. Barclays reissued an “overweight” rating and issued a $80.00 price target (up from $75.00) on shares of Centene in a research report on Wednesday, July 29th. Wells Fargo & Company set a $69.00 price target on shares of Centene and gave the stock an “equal weight” rating in a report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Centene from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Nine analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $70.90.

Centene Price Performance

Shares of CNC opened at $68.79 on Wednesday. Centene has a one year low of $31.63 and a one year high of $72.50. The company has a 50-day moving average of $65.90 and a two-hundred day moving average of $54.94. The stock has a market cap of $33.98 billion, a price-to-earnings ratio of -6.59 and a beta of 1.13.

Centene (NYSE:CNC) last released its earnings results on Tuesday, October 27th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.48. The firm had revenue of $50.65 billion during the quarter, compared to analysts’ expectations of $47.12 billion. The business’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $0.50 earnings per share. Analysts anticipate that Centene will post 4.89 earnings per share for the current year.

Insider Transactions at Centene

In other Centene news, General Counsel Christopher Koster sold 56,500 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $66.90, for a total value of $3,779,850.00. Following the transaction, the general counsel directly owned 248,854 shares of the company’s stock, valued at $16,648,332.60. This represents a 18.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.37% of the company’s stock.

Institutional Trading of Centene

Large investors have recently added to or reduced their stakes in the business. Frank Rimerman Advisors LLC boosted its holdings in Centene by 3.7% in the third quarter. Frank Rimerman Advisors LLC now owns 4,521 shares of the company’s stock worth $281,000 after purchasing an additional 163 shares in the last quarter. Journey Retirement Planning & Investment Management LLC boosted its holdings in Centene by 3.9% during the third quarter. Journey Retirement Planning & Investment Management LLC now owns 4,652 shares of the company’s stock valued at $289,000 after acquiring an additional 175 shares during the period. 180 Wealth Advisors LLC boosted its holdings in Centene by 3.1% during the first quarter. 180 Wealth Advisors LLC now owns 6,683 shares of the company’s stock valued at $219,000 after acquiring an additional 199 shares during the period. Grove Bank & Trust grew its position in shares of Centene by 2.0% in the third quarter. Grove Bank & Trust now owns 11,294 shares of the company’s stock valued at $702,000 after purchasing an additional 220 shares during the last quarter. Finally, GoalVest Advisory LLC increased its stake in shares of Centene by 25.9% in the third quarter. GoalVest Advisory LLC now owns 1,122 shares of the company’s stock worth $70,000 after purchasing an additional 231 shares during the period. 93.63% of the stock is owned by institutional investors.

Key Centene News

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Centene reported third-quarter adjusted diluted EPS of $0.58 versus consensus estimates near $0.07–$0.10, while revenue reached $50.65 billion versus expectations of $47.12 billion. Adjusted results improved from $0.50 per share a year earlier, and the consolidated medical benefit ratio of 92.7% was better than anticipated. Centene Corporation Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised full-year guidance. Centene now expects 2026 adjusted diluted EPS above $5.20, a $0.40 increase, and GAAP diluted EPS above $3.46. Management also said its Medicare business is expected to reach breakeven a year ahead of schedule, supporting the faster earnings-recovery narrative. Centene Forecasts 2026 Adjusted EPS Greater Than $5.20
• Positive Sentiment: Medicare was the key operating bright spot. Medicare revenue reportedly increased 19.9%, and improved cost performance helped offset pressure elsewhere in the business. The results reinforce investor expectations that Centene’s turnaround and cost-control initiatives can lift profitability. Centene Q3 Earnings Beat Estimates on Medicare Strength
• Neutral Sentiment: Heavy put-option buying signals caution but is not proof of worsening fundamentals. Traders purchased 12,127 put options, approximately 72% above typical volume. This may reflect hedging or bearish speculation after the stock’s rally and ahead of earnings. Stock Traders Buy High Volume of Put Options on Centene
• Negative Sentiment: Membership declines remain an overhang. Medicaid membership fell, and Marketplace membership trends require monitoring. These declines could pressure premium growth and partially offset the Medicare turnaround if they persist.

About Centene

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company’s offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.